These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 21076619)

  • 1. Phase 1/2 study of atrasentan combined with pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer.
    Witteveen PO; van der Mijn KJ; Los M; Kronemeijer RH; Groenewegen G; Voest EE
    Neoplasia; 2010 Nov; 12(11):941-5. PubMed ID: 21076619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer.
    Kavanagh JJ; Levenback CF; Ramirez PT; Wolf JL; Moore CL; Jones MR; Meng L; Brown GL; Bast RC
    J Hematol Oncol; 2010 Mar; 3():9. PubMed ID: 20222977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Combined pegylated liposomal doxorubicin and carboplatin in the treatment of recurrent epithelial ovarian cancer].
    Zheng H; Gao YN; Jiang GQ; Gao M; Wang W; Yan X
    Zhonghua Fu Chan Ke Za Zhi; 2008 Nov; 43(11):839-42. PubMed ID: 19087568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer.
    Naumann RW; Coleman RL; Burger RA; Sausville EA; Kutarska E; Ghamande SA; Gabrail NY; Depasquale SE; Nowara E; Gilbert L; Gersh RH; Teneriello MG; Harb WA; Konstantinopoulos PA; Penson RT; Symanowski JT; Lovejoy CD; Leamon CP; Morgenstern DE; Messmann RA
    J Clin Oncol; 2013 Dec; 31(35):4400-6. PubMed ID: 24127448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Panitumumab and pegylated liposomal doxorubicin in platinum-resistant epithelial ovarian cancer with KRAS wild-type: the PaLiDo study, a phase II nonrandomized multicenter study.
    Steffensen KD; Waldstrøm M; Pallisgård N; Lund B; Bergfeldt K; Wihl J; Keldsen N; Marth C; Vergote I; Jakobsen A
    Int J Gynecol Cancer; 2013 Jan; 23(1):73-80. PubMed ID: 23211422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer.
    McGuire WP; Penson RT; Gore M; Herraez AC; Peterson P; Shahir A; Ilaria R
    BMC Cancer; 2018 Dec; 18(1):1292. PubMed ID: 30591028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial.
    Lee EK; Xiong N; Cheng SC; Barry WT; Penson RT; Konstantinopoulos PA; Hoffman MA; Horowitz N; Dizon DS; Stover EH; Wright AA; Campos SM; Krasner C; Morrissey S; Whalen C; Quinn R; Matulonis UA; Liu JF
    Gynecol Oncol; 2020 Oct; 159(1):72-78. PubMed ID: 32771276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salvage chemotherapy in recurrent platinum-resistant or refractory epithelial ovarian cancer with Carboplatin and distearoylphosphatidylcholine pegylated liposomal Doxorubicin (lipo-dox®).
    Khemapech N; Oranratanaphan S; Termrungruanglert W; Lertkhachonsuk R; Vasurattana A
    Asian Pac J Cancer Prev; 2013; 14(3):2131-5. PubMed ID: 23679331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and toxicity of gemcitabine and pegylated liposomal Doxorubicin in recurrent platinum-resistant/refractory epithelial ovarian cancer.
    Karaoglu A; Arslan UY; Ozkan M; Kalender ME; Alici S; Coskun U; Gumus M; Celenkoglu G; Er O; Sevinc A; Buyukberber S; Alkis N; Benekli M;
    Asian Pac J Cancer Prev; 2009; 10(1):63-6. PubMed ID: 19469626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of irinotecan and pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study).
    Shoji T; Takatori E; Omi H; Kagabu M; Honda T; Futagami M; Yokoyama Y; Kaiho M; Tokunaga H; Otsuki T; Takano T; Yaegashi N; Kojimahara T; Ohta T; Nagase S; Soeda S; Watanebe T; Nishiyama H; Sugiyama T
    Cancer Chemother Pharmacol; 2017 Aug; 80(2):355-361. PubMed ID: 28656383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective comparative study of irinotecan and pegylated liposomal doxorubicin for platinum-resistant or -refractory epithelial ovarian and primary peritoneal carcinoma.
    Ichikawa R; Torii Y; Oe S; Kawamura K; Kato R; Hasegawa K; Udagawa Y
    Arch Gynecol Obstet; 2014 Nov; 290(5):979-84. PubMed ID: 24798935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pegylated liposomal doxorubicin consolidation therapy after platinum/paclitaxel-based chemotherapy for suboptimally debulked, advanced-stage epithelial ovarian cancer patients.
    Rocconi RP; Straughn JM; Leath CA; Kilgore LC; Huh WK; Barnes MN; Partridge EE; Alvarez RD
    Oncologist; 2006 Apr; 11(4):336-41. PubMed ID: 16614229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.
    Monk BJ; Herzog TJ; Kaye SB; Krasner CN; Vermorken JB; Muggia FM; Pujade-Lauraine E; Lisyanskaya AS; Makhson AN; Rolski J; Gorbounova VA; Ghatage P; Bidzinski M; Shen K; Ngan HY; Vergote IB; Nam JH; Park YC; Lebedinsky CA; Poveda AM
    J Clin Oncol; 2010 Jul; 28(19):3107-14. PubMed ID: 20516432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pilot study evaluating the efficacy and toxicity of biweekly gemcitabine and pegylated liposomal doxorubicin in recurrent platinum-resistant epithelial ovarian cancer.
    Tas F; Guney N; Derin D; Aydiner A; Topuz E
    Int J Clin Oncol; 2008 Apr; 13(2):156-60. PubMed ID: 18463961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I study of oral topotecan and pegylated liposomal doxorubicin (doxil) in platinum-resistant ovarian and peritoneal cancer.
    Rose PG; Smrekar M; Haba P; Fusco N; Rodriguez M
    Am J Clin Oncol; 2008 Oct; 31(5):476-80. PubMed ID: 18838885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer.
    Kim KH; Jelovac D; Armstrong DK; Schwartz B; Weil SC; Schweizer C; Alvarez RD
    Gynecol Oncol; 2016 Feb; 140(2):210-4. PubMed ID: 26644263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study on pegylated liposomal doxorubicin in combination with docetaxel for patients with platinum-resistant or partially platinum-sensitive epithelial ovarian cancer: The Kansai Clinical Oncology Group study.
    Hori K; Ito K; Kuritani K; Kuji S; Furukawa N; Tsubamoto H; Arakawa A
    J Cancer Res Ther; 2019; 15(6):1201-1206. PubMed ID: 31898647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized phase III study of canfosfamide in combination with pegylated liposomal doxorubicin compared with pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer.
    Vergote I; Finkler NJ; Hall JB; Melnyk O; Edwards RP; Jones M; Keck JG; Meng L; Brown GL; Rankin EM; Burke JJ; Boccia RV; Runowicz CD; Rose PG
    Int J Gynecol Cancer; 2010 Jul; 20(5):772-80. PubMed ID: 20973267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens.
    Parma G; Mancari R; Del Conte G; Scambia G; Gadducci A; Hess D; Katsaros D; Sessa C; Rinaldi A; Bertoni F; Vitali A; Catapano CV; Marsoni S; van de Velde H; Colombo N
    Int J Gynecol Cancer; 2012 Jun; 22(5):792-800. PubMed ID: 22635029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trabectedin plus pegylated liposomal doxorubicin (PLD) for patients with platinum-sensitive recurrent ovarian cancer: a prospective, observational, multicenter study.
    Runnebaum IB; Reichert D; Ringsdorf U; Kuther M; Hesse T; Sehouli J; Wimberger P
    J Cancer Res Clin Oncol; 2018 Jun; 144(6):1185-1195. PubMed ID: 29623421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.